Home/Pipeline/Peripheral CD38 Program

Peripheral CD38 Program

Parkinson's Disease

DiscoveryActive

Key Facts

Indication

Parkinson's Disease

Phase

Discovery

Status

Active

Company

Verge Genomics

About Verge Genomics

Verge Genomics is a private, clinical-stage biotech leveraging a proprietary AI platform, CONVERGE®, to discover and develop novel therapeutics. The company's lead program, VRG50635, a PIKfyve inhibitor for ALS, is in Phase 1, marking a key milestone of discovering a novel target and developing a clinical candidate entirely in-house. With a pipeline spanning neuroscience, metabolic, and immunology indications, Verge aims to address diseases with complex biology and high unmet need. The company is led by a team combining drug development expertise with technology leadership.

View full company profile

Therapeutic Areas

Neuroscience Metabolic Immunology Rare Diseases

Other Parkinson's Disease Drugs

Drug	Company	Phase	Status
NPT200-11	Neuropore Therapies	Phase 1	Partnered (UCB Pharma), status unclear
NUZ-001	Neurizon Therapeutics	Preclinical	Active
VXX-301	Vaxxinity	Preclinical	Pipeline
BAN2802	BioArctic	Phase 1	Active
CNM-Au8	Clene	Phase 2	Active
hpSC-Derived Neural/Dopaminergic Cells	International Stem Cell	Preclinical/Early Clinical	Inferred Active
SLS-004	Seelos Therapeutics	Preclinical	Research
SLS-007	Seelos Therapeutics	Preclinical	Research
Parkinson's Disease Portfolio (Platform-derived)	WD Pharmaceutical	Not Disclosed (Likely Preclinical/Early Clinical)	Active
UX-DA001	UniXell	Phase 1	Active, with trials ongoing in China and FDA IND cleared in U.S. (as of April 2025)
Parkinson's Disease Research	ProgenaBiome	Research	Active
A9 Dopaminergic Neuron Therapy	Trailhead Biosystems	Pre-clinical	Active